Evidence map›Paper›PMID 40191716›Full record

ArticleOncology research2025

A Nomogram for Predicting Survival for Patients with Brain Metastatic and

Jiyun Pang, Weigang Xiu, Yueyun Chen, Wenjing Liao, Qin Zhang, Huashan Shi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiyun PangDepartment of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Weigang XiuDepartment of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yueyun ChenDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Wenjing LiaoDepartment of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Qin ZhangWest China School of Medicine, Department of Postgraduate Students, Sichuan University, Chengdu, 610041, China.
Huashan ShiDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Non-small cell lung cancer (NSCLC) is often accompanied by brain metastasis (BM), and the prognosis of patients with BM is poor. This study assesses the prognostic impact of BM in NSCLC patients with epidermal growth factor receptor ( Methods: We retrospectively evaluated 692 advanced NSCLC patients with Results: NSCLC patients with BM exhibited a higher frequency of other-site and multi-organ metastases than those without BM. The BM group demonstrated significantly worse OS (26.2 Conclusions: BM is a significant risk factor for NSCLC patients, potentially linked to lymphocytopenia.

Indexed as

Brain NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsMutationNomogramsAdultAgedAged, 80 and overErbB ReceptorsFemaleHumansMaleMiddle AgedPrognosisProtein Kinase InhibitorsRetrospective StudiesEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsBrain metastasis (BM)Epidermal growth factor receptor (EGFR)Non-small cell lung cancer (NSCLC)Tumor microenvironmentTyrosine kinase inhibitor (TKI)

Identifiers

PMID40191716
PMCPMC11964887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.